FDA approves Gilead's HCV triple combo

FDA approved Vosevi sofosbuvir/velpatasvir/voxilaprevir from Gilead Sciences Inc. (NASDAQ:GILD) as a salvage therapy for chronic HCV infection without cirrhosis or with mild cirrhosis.

Vosevi is indicated for HCV genotypes 1-6 infection in adults previously treated with a regimen containing an HCV NS5A protein inhibitor, and for HCV genotypes 1a and 3 infection in adults previously treated with a regimen containing Gilead's Sovaldi sofosbuvir without an HCV NS5A protein inhibitor. Sovaldi is a nucleotide analog HCV NS5B polymerase inhibitor...